Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.49 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.48 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.47 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.47 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 8/20 | 0.42 |
| ▸ | RAB9A | P51151 | 8/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29850747 | 0.83 | NCF1 (0.52) | NCF1DDB1CRBNSSTR4NPC1 | |
| SCHEMBL12723436 | 0.82 | NPC1 (0.50) | NCF1DDB1CRBNHDAC3HDAC4 | |
| SCHEMBL5943516 | 0.74 | IRAK4 (0.52) | NCF1DDB1CRBNNPC1RAB9A | |
| SCHEMBL31620776 | 0.74 | NCF1 (0.57) | NCF1DDB1CRBNNPC1RAB9A | |
| SCHEMBL24969944 | 0.74 | SSTR4 (0.36) | SSTR4RAB9AKMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL31142917 | 0.74 | SSTR4 (0.36) | SSTR4RAB9AKMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL1012347 | 0.74 | HDAC3 (0.58) | NCF1DDB1CRBNHDAC3HDAC4 | |
| SCHEMBL7841601 | 0.73 | NCF1 (0.52) | NCF1DDB1CRBNHDAC3HDAC4 | |
| Hydrochloric Acid SCHEMBL2417124 | 0.73 | IRAK4 (0.51) | NCF1DDB1CRBNNPC1RAB9A | |
| Hydrochloric Acid SCHEMBL30903344 | 0.73 | SSTR4 (0.36) | SSTR4RAB9AKMT2AKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932246-B2 | Histone deacetylase inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2011-04-26 | — | — | US | disclosed |
| US-7932246-B2 | Histone deacetylase inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2011-04-26 | — | — | US | disclosed |
| US-7932246-B2 | Histone deacetylase inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2011-04-26 | — | — | US | disclosed |
| EP-1881977-B1 | HISTONE DEACETYLASE INHIBITORS | CHROMA THERAPEUTICS LTD (GB) | 2011-01-05 | — | — | EP | disclosed |
| EP-1881977-B1 | HISTONE DEACETYLASE INHIBITORS | CHROMA THERAPEUTICS LTD (GB) | 2011-01-05 | — | — | EP | disclosed |
| US-20100152155-A1 | Histone Deacetylase Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2010-06-17 | — | — | US | disclosed |
| US-20100152155-A1 | Histone Deacetylase Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2010-06-17 | — | — | US | disclosed |
| US-20100152155-A1 | Histone Deacetylase Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2010-06-17 | — | — | US | disclosed |
| EP-1881977-A1 | HISTONE DEACETYLASE INHIBITORS | Chroma Therapeutics Limited (GB) | 2008-01-30 | — | — | EP | disclosed |
| WO-2006123121-A1 | HISTONE DEACETYLASE INHIBITORS | CHROMA THERAPEUTICS LTD (GB) | 2006-11-23 | — | — | WO | disclosed |
| WO-2006123121-A1 | HISTONE DEACETYLASE INHIBITORS | CHROMA THERAPEUTICS LTD (GB) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152155-A1 | Histone Deacetylase Inhibitors | HDAC1, HDAC2, HDAC11 | NCF1 972/4885DDB1 1122/4885CRBN 2359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.